Data / Drug companies / Daptomycin
Daptomycin: 25 companies and 49 products in the FDA NDC directory
Daptomycin is listed in the FDA National Drug Code Directory by 25 companies, with 49 products in commercial distribution. 34 of the products (69.4%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution; injection, powder, lyophilized, for suspension, and the newest product started marketing on October 22, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 25
- Products
- 49
- Generic (ANDA) products
- 34 (69.4%)
- Application numbers
- 25
- Routes
- Intravenous
- Brand names
- Dapzura RT
- openFDA record search
- api.fda.gov
Companies that list daptomycin
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | 5 | injection, powder, lyophilized, for solution | New drug applications (NDA) | October 22, 2026 |
| Meitheal Pharmaceuticals Inc. | 5 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 5, 2022 |
| Xellia Pharmaceuticals USA LLC | 5 | injection, powder, lyophilized, for solution | New drug applications (NDA) | November 3, 2023 |
| Civica, Inc. | 3 | injection, powder, lyophilized, for solution | New drug applications (NDA) | November 28, 2025 |
| Sagent Pharmaceuticals | 3 | injection, powder, lyophilized, for solution | New drug applications (NDA) | February 1, 2020 |
| Accord Healthcare Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 16, 2019 |
| Be Pharmaceuticals Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 20, 2020 |
| Camber Pharmaceuticals, Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 23, 2022 |
| Dr. Reddy's Laboratories Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 4, 2021 |
| Fresenius Kabi USA, LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 11, 2018 |
| Hospira, Inc. | 2 | injection, powder, lyophilized, for solution | New drug applications (NDA) | August 2, 2021 |
| Mylan Institutional LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 27, 2023 |
| NorthStar RxLLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 18, 2023 |
| Apotex Corp. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 23, 2022 |
| Aspiro Pharma Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 23, 2022 |
| Baxter Healthcare Corporation | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | January 25, 2022 |
| Biocon Pharma Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 25, 2024 |
| BluePoint Laboratories | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 1, 2019 |
| Eugia US LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 2, 2021 |
| Hainan Poly Pharm. Co., Ltd. | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | November 14, 2023 |
| Maia Pharmaceuticals, Inc. | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | September 8, 2025 |
| Par Health USA, LLC | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | October 27, 2025 |
| Qilu Pharmaceutical Co., Ltd. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 24, 2021 |
| Sintetica US LLC | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | November 5, 2023 |
| Slate Run Pharmaceuticals, LLC | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | October 1, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 46 | 93.9% |
| Injection, powder, lyophilized, for suspension | 3 | 6.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 34 | 69.4% |
| New drug applications (NDA) | 15 | 30.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Lipopeptide Antibacterial | 49 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.